SOURCE: SNN Incorporated

SNN Incorporated

December 14, 2015 08:30 ET

StockNewsNow.com Publishes New SNNLive Video Interview with Amarantus BioScience Holdings, Inc.

LOS ANGELES, CA--(Marketwired - December 14, 2015) - StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Gerald Commissiong, President and CEO of Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing product candidates in Regenerative Medicine and Orphan Diseases, according to the Company's website (see here: www.Amarantus.com). The video interview was recorded at the LD Micro "Main Event" on December 2nd, 2015 in Bel Air, CA.

Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:

Year-End Review with Amarantus BioScience Holdings, Inc. -- Discusses Severe Burns, Parkinson's Clinical Trials, MANF Pre-Clinical Work and Diagnostics

You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS

Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer

About Amarantus BioScience Holdings, Inc. 

Amarantus BioScience Holdings (OTCQX: AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology and orphan diseases. The Company has an exclusive worldwide license to intellectual property rights associated to Engineered Skin Substitute (ESS), an orphan drug designated autologous full thickness skin replacement product in development for the treatment of adult severe burns currently preparing to enter Phase 2 clinical studies. The Company is currently evaluating human clinical data from previously conducted studies in pediatric severe burns and Congenital Giant Hairy Nevus to support clinical development expansion into those areas. AMBS also has development rights to eltoprazine, a small molecule currently in a Phase 2b clinical program for Parkinson's disease levodopa-induced dyskinesia with the potential to expand into adult ADHD and Alzheimer's aggression. AMBS owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF as a treatment for orphan ophthalmic disorders, initially in retinitis pigmentosa (RP) and retinal artery occlusion (RAO). AMBS also owns the discovery of neurotrophic factors (PhenoGuard) that led to MANF's discovery.

AMBS' Diagnostics division owns the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro).

For further information please visit http://www.Amarantus.com, or connect with the Company on FacebookLinkedInTwitter and Google+.

About StockNewsNow.com

StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature user-generated video, SNN-produced video like SNNLive CEO video interviews, as well as articles, and their latest news and headlines. Users can engage directly and share the information provided through social media.

Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for -- all here on StockNewsNow.com.

Embedded Video Available: https://www.youtube.com/watch?v=ZJFauxzffVg

Contact Information